Journal
Thyroid
Publication Date
1-1-2024
Volume
34
Issue
1
First Page
26
Last Page
40
Document Type
Open Access Publication
DOI
10.1089/thy.2023.0363
Rights and Permissions
Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 Jan;34(1):26-40. doi: 10.1089/thy.2023.0363. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Subbiah, Vivek; Adkins, Douglas; and et al., "Pralsetinib in patients with advanced/metastatic rearranged during transfection (RET)-altered thyroid cancer: Updated efficacy and safety data from the ARROW study." Thyroid. 34, 1. 26 - 40. (2024).
https://digitalcommons.wustl.edu/oa_4/3624
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
